FDA Rejects Apitegromab for SMA Due to Fill-Finish Concerns
The FDA issued a Complete Response Letter for Scholar Rock's apitegromab BLA due to manufacturing observations at a third-party facility, but no other approval issues were cited. Scholar Rock plans to resubmit after remediation of the manufacturing concerns, maintaining optimism about the drug's potential to treat SMA.
